Evogene Cuts Expenses to $13.8M, Secures $3.4M Warrant Proceeds
Evogene cut operating expenses to $13.8M in 2025 from $22.0M, with Q4 costs down to $3.2M from $4.3M, and secured $3.4M gross proceeds via warrant exercises at $1.25 per share. The company sharpened focus on its ChemPass AI engine, training a 38B-structure model achieving 90% design precision.
1. Strategic Restructuring and Focus
Evogene shifted to a single proprietary technology engine, ChemPass AI, for small-molecule discovery in pharma and agriculture, discontinuing non-core activities, divesting misaligned assets, and resizing its organization to concentrate resources on high-impact markets.
2. AI Collaborations and Model Performance
The company advanced ChemPass AI through collaborations with Google Cloud, training a foundation model on 38 billion structures that achieved 90% design precision, and launched an integration with Google Cloud Vertex AI agents in February 2026 to automate workflows and enhance candidate quality.
3. Cost Reductions and Capital Raise
Organizational realignment cut operating expenses to $13.8 million in 2025 from $22.0 million in 2024, with Q4 expenses falling to $3.2 million. In February 2026, warrant exercises generated approximately $3.4 million in gross proceeds, with new warrants exercisable at $1.25 per share.
4. Divestitures of Non-Core Subsidiaries
Evogene completed the sale of Lavie Bio’s operations to ICL, licensed Biomica’s lead candidate BMC128 to Lishan Pharmaceuticals, and recorded a $2.2 million impairment at Casterra Ag, positioning these entities for cash distributions to shareholders.